ATE522540T1 - Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten - Google Patents
Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheitenInfo
- Publication number
- ATE522540T1 ATE522540T1 AT07718885T AT07718885T ATE522540T1 AT E522540 T1 ATE522540 T1 AT E522540T1 AT 07718885 T AT07718885 T AT 07718885T AT 07718885 T AT07718885 T AT 07718885T AT E522540 T1 ATE522540 T1 AT E522540T1
- Authority
- AT
- Austria
- Prior art keywords
- short interfering
- interfering ribonucleic
- treatment
- ribonucleic acids
- gene rna
- Prior art date
Links
- 208000026935 allergic disease Diseases 0.000 title abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 2
- 230000007815 allergy Effects 0.000 title abstract 2
- 230000002452 interceptive effect Effects 0.000 title abstract 2
- 229920002477 rna polymer Polymers 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 208000037883 airway inflammation Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006902491A AU2006902491A0 (en) | 2006-05-11 | Short interference ribonucleic acids for treating allergic diseases | |
| PCT/AU2007/000638 WO2007131274A1 (en) | 2006-05-11 | 2007-05-11 | Short interference ribonucleic acids for treating allegic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522540T1 true ATE522540T1 (de) | 2011-09-15 |
Family
ID=38693443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07718885T ATE522540T1 (de) | 2006-05-11 | 2007-05-11 | Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8188262B2 (de) |
| EP (1) | EP2018395B1 (de) |
| JP (1) | JP2009536518A (de) |
| CN (1) | CN101437835B (de) |
| AT (1) | ATE522540T1 (de) |
| ES (1) | ES2372982T3 (de) |
| TW (1) | TWI322690B (de) |
| WO (1) | WO2007131274A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120029054A1 (en) * | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| JP2013079210A (ja) * | 2011-10-04 | 2013-05-02 | Nagoya City Univ | 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法 |
| US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| WO2015051318A1 (en) | 2013-10-04 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
| US20150376612A1 (en) * | 2014-06-10 | 2015-12-31 | The General Hospital Corporation | CCCTC-Binding Factor (CTCF) RNA Interactome |
| PL3093022T3 (pl) * | 2015-05-15 | 2020-02-28 | Sterna Biologicals Gmbh & Co. Kg | Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2 |
| RU2615463C1 (ru) * | 2016-01-28 | 2017-04-04 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Способ лечения аллергической бронхиальной астмы, основанный на подавлении экспрессии генов цитокинов IL-4 и IL-13 с использованием молекул миРНК |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996034887A2 (en) * | 1995-05-05 | 1996-11-07 | Imperial College Of Science, Technology & Medicine | Antisense peptides |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6136603A (en) * | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
| AU2002256359A1 (en) * | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
| US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US20050261219A1 (en) * | 2001-05-18 | 2005-11-24 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
| EP2305813A3 (de) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Funktionale und hyperfunktionale siRNA |
| DE10346487A1 (de) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
-
2007
- 2007-05-04 TW TW096115998A patent/TWI322690B/zh active
- 2007-05-11 JP JP2009508057A patent/JP2009536518A/ja active Pending
- 2007-05-11 CN CN2007800167313A patent/CN101437835B/zh active Active
- 2007-05-11 US US12/300,337 patent/US8188262B2/en active Active
- 2007-05-11 ES ES07718885T patent/ES2372982T3/es active Active
- 2007-05-11 EP EP07718885A patent/EP2018395B1/de active Active
- 2007-05-11 WO PCT/AU2007/000638 patent/WO2007131274A1/en not_active Ceased
- 2007-05-11 AT AT07718885T patent/ATE522540T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200806302A (en) | 2008-02-01 |
| HK1130065A1 (en) | 2009-12-18 |
| US20090264503A1 (en) | 2009-10-22 |
| US8188262B2 (en) | 2012-05-29 |
| CN101437835A (zh) | 2009-05-20 |
| CN101437835B (zh) | 2012-10-10 |
| JP2009536518A (ja) | 2009-10-15 |
| WO2007131274A1 (en) | 2007-11-22 |
| AU2007250524B2 (en) | 2012-11-01 |
| AU2007250524A1 (en) | 2007-11-22 |
| EP2018395A4 (de) | 2009-12-09 |
| EP2018395B1 (de) | 2011-08-31 |
| TWI322690B (en) | 2010-04-01 |
| ES2372982T3 (es) | 2012-01-30 |
| EP2018395A1 (de) | 2009-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007084391A3 (en) | Thiazole compounds as protein kinase b ( pkb) inhibitors | |
| EA200870528A1 (ru) | Композиции и способы ингибирования экспрессии гена pcsk9 | |
| WO2013074974A3 (en) | Modified rnai agents | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| WO2009050506A3 (en) | Combination 059 | |
| WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
| TW201712023A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| EA200870401A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5 | |
| WO2004065601A3 (en) | Lipophilic derivatives of double-stranded ribonucleic acid | |
| TW200806302A (en) | Short interference ribonucleic acids for treating allergic dieases | |
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| WO2012046085A3 (en) | Methods of inducing insulin production | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| WO2008036638A3 (en) | Rnai modulation of scap and therapeutic uses thereof | |
| WO2007137156A3 (en) | Rnai modulation of aha and therapeutic uses thereof | |
| MY149171A (en) | Treatment and prevention of influenza | |
| WO2010003420A3 (en) | Treatment of psoriasis and related diseases by mirna modulation | |
| WO2006093547A3 (en) | Novel lipoxygenase inhibitors | |
| WO2011087835A3 (en) | Novel compositions and methods for treating inflammatory bowel disease and airway inflammation | |
| WO2011045573A3 (en) | Staphylococcal antigens | |
| WO2008051523A3 (en) | Carbazole derivatives useful as medicaments in cancer therapy | |
| WO2009138146A3 (de) | Neue therapeutika für die hepatitis-therapie | |
| WO2009012785A3 (en) | Complexes of an emulgator and a fatty acid | |
| WO2005001031A3 (en) | Modulation of the rna interference pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |